 |
The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
Technology is continually changing, but FDA’s commitment to public health does not. In today’s world, a tremendous amount of information exchange occurs on the web and through social media. In 2014, FDA’s Office of Prescription Drug Promotion (OPDP) released three highly-anticipated draft guidances detailing FDA’s current views and recommendations on specific social media topics.
To further our communications with stakeholders, media and the public in this area, FDA will host a webinar and Q&A session on July 10, 2014, from 2:00-3:00 p.m. (EST).
The purpose of this webinar is to provide an introduction and overview of FDA’s three recently issued social media draft guidances: Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics, Internet/Social Media Platforms with Character Space Limitations— Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices and Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices.
Subject-matter experts will also be available to answer questions regarding the draft guidances and provide further explanation of key concepts; questions/comments can be submitted live via a Q/A chat window.
Additional information is located at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm397791.htm
To register for this event, please go the following link: http://go.usa.gov/XxMJ (Your registration password needs to be 8 characters and alphanumeric)
Note: Your registration acknowledgement will include the webinar access link. Registration is limited, so please register now.
Audio will broadcast from your computer speakers, and closed captioning will be provided.
To access the public docket or leave comments regarding the draft guidances, please visit:
• Draft Guidance for Industry and Staff: Internet/Social Media Platforms with Character Space Limitations; Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices (FR Notice)
• Draft Guidance for Industry and Staff: Internet/Social Media Platforms; Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices (FR Notice)
This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm Monday - Friday. You can also email us at druginfo@fda.hhs.gov.
- For additional drug information, please visit the DDI Web page.
- For up-to-date drug information, follow the FDA’s Division of Drug Information on Twitter: FDA_Drug_Info
- This service is provided to you at no charge by the U.S. Food & Drug Administration (FDA).
| This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
